Selinexor (KPT-330) 1393477-72-9 Karyopharm Therapeutics, Inc. WO2011109799A1 WO2013019548A1 C17-H11-F6-N7-O 443.3099 Synonyms (Z)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N’-(pyrazin-2-yl)acrylohydrazide 2-Propenoic acid, 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-, 2-(2-pyrazinyl)hydrazide, (2Z)- 3-[3-[3,5-Bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-N’-(pyrazin-2-yl)acrylohydrazide KPT-330 Selinexor Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in Patients with … MarketWatch “These patients were treated in our Phase 1 clinical trial of Selinexor in … Additional Phase 1 and Phase 2 … Continue reading Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) an orphan drug